# Azeliragon in MGMT Unmethylated Glioblastoma

Source: https://onco.cc/trials/nct05986851/  
OnCo record `nct05986851` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Azeliragon in glioma & glioblastoma, run by Cantex Pharmaceuticals, active and no longer recruiting.

## Summary

Azeliragon in MGMT Unmethylated Glioblastoma is a phase 2 interventional study registered as NCT05986851 by Cantex Pharmaceuticals, with 30 participants enrolled, started 2023-09-12 and due to reach its primary completion in 2026-09-30. Interventions recorded: Azeliragon.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05986851
- Phase: 2
- Setting: A Phase II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients With MGMT Unmethylated Glioblastoma
- Sponsor: Cantex Pharmaceuticals
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05986851: https://clinicaltrials.gov/study/NCT05986851

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- companies: [Medpace](https://onco.cc/companies/medpace/)

---
JSON: https://onco.cc/api/v1/entities/nct05986851.json